The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of ICI plus chemotherapy or ipilimumab plus nivolumab based therapy for patients with NSCLC with TPS (1-49%): TOPGAN2023-01.
 
Takehiro Tozuka
Honoraria - AstraZeneca Japan; Chugai Pharma
 
Hisashi Tanaka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical; Pfizer
 
Tomonori Makiguchi
Honoraria - Asahi KASEI; AstraZeneca Japan; Chugai Pharma; Eli Lill; GlaxoSmithKline; LTD; Nippon Boehringer Ingelheim; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - KAKENHI JSPS
 
Yosuke Kawashima
Honoraria - AstraZeneca Japan; Chugai Pharma; Kyowa Kirin; Life Technologies; Lilly; Taiho Pharmaceutical
 
Tomohiro Oba
No Relationships to Disclose
 
Ryosuke Tsugitomi
No Relationships to Disclose
 
Junji Koyama
Honoraria - AstraZeneca Japan; Chugai Pharma
Patents, Royalties, Other Intellectual Property - Patentes pending(JP2022-043291, PCT/JP2023/008495)
 
Yuichi Tambo
Honoraria - Chugai Pharma; Daiichi Sankyo; MSD K.K; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Regeneron (Inst); Roche (Inst); Taiho Pharmaceutical (Inst)
 
Shinsuke Ogusu
Speakers' Bureau - Bristol-Myers Squibb; Chugai Pharma; MSD
Travel, Accommodations, Expenses - Chugai Pharma
 
Masafumi Saiki
No Relationships to Disclose
 
Hiroshi Gyotoku
No Relationships to Disclose
 
Tsukasa Hasegawa
Honoraria - AstraZeneca Japan; Chugai Pharma; Lilly; Merck Sharp & Dohme
 
Eisaku Miyauchi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Meyers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyorin; Kyowa Kirin; Kyowa Kirin Co Ltd; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Takeda; Thermo Fisher Scientific
Consulting or Advisory Role - Boehringer Ingelheim; Daiichi Sankyo KK; Merck; Ono Pharmaceutical
 
Tomoaki Sonoda
No Relationships to Disclose
 
Ryota Saito
No Relationships to Disclose
 
Katsumi Nakatomi
No Relationships to Disclose
 
Toshio Sakatani
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Lilly Japan; MSD; Taiho Pharmaceutical; Takeda
 
Keita Kudo
No Relationships to Disclose
 
Yuko Tsuchiya-Kawano
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Hakko Kirin; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
 
Makoto Nishio
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Janssen; Lilly; Merck; MSD; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)